Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 7.85
AGEN's Cash to Debt is ranked higher than
69% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. AGEN: 7.85 )
AGEN' s 10-Year Cash to Debt Range
Min: 0.24   Max: No Debt
Current: 7.85

Equity to Asset 0.58
AGEN's Equity to Asset is ranked higher than
65% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. AGEN: 0.58 )
AGEN' s 10-Year Equity to Asset Range
Min: -1.33   Max: 0.92
Current: 0.58

-1.33
0.92
F-Score: 3
Z-Score: -6.00
M-Score: -3.47
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -820.36
AGEN's Operating margin (%) is ranked higher than
56% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. AGEN: -820.36 )
AGEN' s 10-Year Operating margin (%) Range
Min: -11732.38   Max: -42.23
Current: -820.36

-11732.38
-42.23
Net-margin (%) -987.62
AGEN's Net-margin (%) is ranked higher than
56% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. AGEN: -987.62 )
AGEN' s 10-Year Net-margin (%) Range
Min: -11762.54   Max: -70.95
Current: -987.62

-11762.54
-70.95
ROA (%) -86.33
AGEN's ROA (%) is ranked higher than
54% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. AGEN: -86.33 )
AGEN' s 10-Year ROA (%) Range
Min: -117.51   Max: -32.36
Current: -86.33

-117.51
-32.36
ROC (Joel Greenblatt) (%) -896.95
AGEN's ROC (Joel Greenblatt) (%) is ranked higher than
65% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -243.56 vs. AGEN: -896.95 )
AGEN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -896.95   Max: -182.27
Current: -896.95

-896.95
-182.27
Revenue Growth (%) -21.90
AGEN's Revenue Growth (%) is ranked higher than
64% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. AGEN: -21.90 )
AGEN' s 10-Year Revenue Growth (%) Range
Min: -54.7   Max: 100
Current: -21.9

-54.7
100
EBITDA Growth (%) 2.70
AGEN's EBITDA Growth (%) is ranked higher than
83% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. AGEN: 2.70 )
AGEN' s 10-Year EBITDA Growth (%) Range
Min: -51   Max: 17
Current: 2.7

-51
17
EPS Growth (%) -7.40
AGEN's EPS Growth (%) is ranked higher than
79% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. AGEN: -7.40 )
AGEN' s 10-Year EPS Growth (%) Range
Min: -40   Max: 19.4
Current: -7.4

-40
19.4
» AGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

AGEN Guru Trades in Q2 2013

Robert Bruce 233,515 sh (unchged)
» More
Q3 2013

AGEN Guru Trades in Q3 2013

Robert Bruce 233,515 sh (unchged)
» More
Q4 2013

AGEN Guru Trades in Q4 2013

Paul Tudor Jones 28,000 sh (New)
Robert Bruce 233,515 sh (unchged)
» More
Q1 2014

AGEN Guru Trades in Q1 2014

Jean-Marie Eveillard 200,000 sh (New)
George Soros 102,200 sh (New)
Robert Bruce 233,515 sh (unchged)
Paul Tudor Jones 17,411 sh (-37.82%)
» More
» Details

Insider Trades

Latest Guru Trades with AGEN

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-03-31 New Buy$2.64 - $5.1 $ 3.05-13%200000
George Soros 2014-03-31 New Buy$2.64 - $5.1 $ 3.05-13%102200
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.00
AGEN's P/B is ranked higher than
84% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 5.51 vs. AGEN: 3.00 )
AGEN' s 10-Year P/B Range
Min: 2.08   Max: 37.35
Current: 3

2.08
37.35
P/S 40.40
AGEN's P/S is ranked higher than
66% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 19.16 vs. AGEN: 40.40 )
AGEN' s 10-Year P/S Range
Min: 4.61   Max: 3564
Current: 40.4

4.61
3564
EV-to-EBIT -3.93
AGEN's EV-to-EBIT is ranked higher than
55% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AGEN: -3.93 )
AGEN' s 10-Year EV-to-EBIT Range
Min: 10.4   Max: 21.3
Current: -3.93

10.4
21.3
Current Ratio 5.24
AGEN's Current Ratio is ranked higher than
77% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. AGEN: 5.24 )
AGEN' s 10-Year Current Ratio Range
Min: 0.64   Max: 42.49
Current: 5.24

0.64
42.49
Quick Ratio 5.24
AGEN's Quick Ratio is ranked higher than
79% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. AGEN: 5.24 )
AGEN' s 10-Year Quick Ratio Range
Min: 0.64   Max: 42.49
Current: 5.24

0.64
42.49

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.60
AGEN's Price/Net Cash is ranked higher than
88% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 65.19 vs. AGEN: 6.60 )
AGEN' s 10-Year Price/Net Cash Range
Min: 3.12   Max: 46.46
Current: 6.6

3.12
46.46
Price/Net Current Asset Value 6.60
AGEN's Price/Net Current Asset Value is ranked higher than
87% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 44.88 vs. AGEN: 6.60 )
AGEN' s 10-Year Price/Net Current Asset Value Range
Min: 3.09   Max: 45.8
Current: 6.6

3.09
45.8
Price/Tangible Book 5.40
AGEN's Price/Tangible Book is ranked higher than
80% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 8.78 vs. AGEN: 5.40 )
AGEN' s 10-Year Price/Tangible Book Range
Min: 2.28   Max: 15.51
Current: 5.4

2.28
15.51
Price/Median PS Value 1.50
AGEN's Price/Median PS Value is ranked higher than
75% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. AGEN: 1.50 )
AGEN' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 115.32
Current: 1.5

0.2
115.32
Earnings Yield (Greenblatt) 879.80
AGEN's Earnings Yield (Greenblatt) is ranked higher than
97% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. AGEN: 879.80 )
AGEN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.7   Max: 1119.8
Current: 879.8

4.7
1119.8
Forward Rate of Return (Yacktman) -54.85
AGEN's Forward Rate of Return (Yacktman) is ranked higher than
61% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: -10.54 vs. AGEN: -54.85 )
AGEN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -110.3   Max: -72.9
Current: -54.85

-110.3
-72.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AJ81.Germany
Agenus, Inc. was formerly known as Antigenics Inc. is a biotechnology company incorporated in 1994, which develops and commercializes technologies to treat cancers and infectious diseases, mainly based on immunological approaches. Its advanced product, Oncophage (vitespen), is a patient-specific therapeutic cancer vaccine registered for use in Russia and under review by the European Medicines Agency for the treatment of kidney cancer patients with earlier-stage disease. Oncophage has been tested in Phase 3 clinical trials for the treatment of renal cell carcinoma, the most common type of kidney cancer, and for metastatic melanoma, and it has also been tested in Phase 1 and Phase 2 clinical trials in a range of indications and is currently in a Phase 2 clinical trial in recurrent glioma, a type of brain cancer. The Company's product candidate portfolio includes: QS-21 Stimulon adjuvant, or QS-21, which is used in numerous vaccines under development in trials, some as advanced as Phase 3, for a number of diseases, including hepatitis, human immunodeficiency virus, influenza, cancer, Alzheimer's disease, malaria, and tuberculosis, and Aroplatin, a liposomal chemotherapeutic tested in a Phase 1 clinical trial for the treatment of solid malignancies and B-cell lymphomas. The Company's business activities include product research and development, intellectual property prosecution, manufacturing therapeutic vaccines for clinical trials, regulatory and clinical affairs, corporate finance and development activities, market development, and support of its collaborations. The Company faces intense competition from major pharmaceutical companies and specialized biotechnology companies engaged in the development of product candidates directed at cancer and infectious diseases. Several of these companies have products that utilize similar technologies and/or patient-specific medicine techniques, such as Dendreon and Accentia. The Company is also subject to regulation under the Occupational Safety and Health Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act, and other current and potential future federal, state, or local regulations.
» More Articles for AGEN

Headlines

Articles On GuruFocus.com
Agenus: Grossly Undervalued GlaxoSmithKline Acquisition Target Sep 10 2012 
5 Speculative Biotech Stocks to Consider Buying Now Jan 24 2012 
Weekly CEO Buys Highlight: CTAS, VRX, TAT, AGEN, MRK Aug 20 2011 
Chairman & CEO of Agenus Inc. (AGEN) Garo Armen Buys 2,150,976 Shares Aug 18 2011 
Antigenics Inc. Reports Operating Results (10-K) Mar 16 2011 
Antigenics Inc. Reports Operating Results (10-Q) Nov 09 2010 
Antigenics Inc. (AGEN) CFO Shalini Sharp sells 1,500 Shares Oct 28 2010 
Antigenics Inc. (AGEN) CFO Shalini Sharp sells 2,000 Shares Sep 14 2010 
Antigenics Inc. (AGEN) CFO Shalini Sharp sells 1,520 Shares Jul 28 2010 
Antigenics Inc. Reports Operating Results (10-Q) May 07 2010 

More From Other Websites
Agenus to Report Second Quarter 2014 Financial Results on July 24, 2014; Conference Call to Follow Jul 17 2014
Agenus to Report Second Quarter 2014 Financial Results on July 24, 2014; Conference Call to Follow Jul 17 2014
Agenus Up on Positive Prophage Data Jul 02 2014
Regeneron Pharmaceuticals (REGN) Jumps: Stock Gains 7.4% Jul 02 2014
Agenus Inc. (AGEN) Soars: Stock Adds 10.3% in Session Jul 02 2014
Why Agenus (AGEN) Stock Is Spiking Today Jul 01 2014
AGENUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 01 2014
Agenus Brain Cancer Vaccine Shows Extended Survival in Phase 2 Final Data Analysis Jul 01 2014
Agenus brain cancer vaccine doubles survival rate in study Jul 01 2014
Agenus brain cancer vaccine nearly doubles survival rate in study Jul 01 2014
AGENUS INC Files SEC form 8-K, Change in Directors or Principal Officers Jun 30 2014
AGENUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 27 2014
AGENUS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jun 16 2014
Agenus Selected for Inclusion in the Russell 3000 Index and Global Index Jun 16 2014
Earnings Estimates Moving Higher for Agenus (AGEN): Time to Buy? Jun 06 2014
Can the Uptrend Continue for Agenus (AGEN)? Jun 02 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide